echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Two days three target drugs approved 2020 is doomed to extraordinary!

    Two days three target drugs approved 2020 is doomed to extraordinary!

    • Last Update: 2020-05-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wenyu cakethe field of cancer not only the rapid development of new drugs, the speed of approval is also exciting, in just two days, RET/ MET/PARP three targets of the new drug approved by the FDA, which is destined to extraordinary 2020 brings infinite vitalityToday we'll take a look at these three target drugsMay 8, FDA accelerated the approval of Lilly's LoxoOncology LOXO-292 capsules for treatment: (1) adult metastatic RET fusion-positive NSCLC Patients; (2) adults requiring systematic treatment and patients with advanced or metastatic RET-positive thyroid myelin cancer in pediatrics over 12 years of age; (3) adults with critical or metastatic RET fusion-positive thyroid cancer in pediatrics with critical or metastatic RET retication for critical and difficult treatment of radioactive iodinethe incidence of RET gene fusion in NSCLC patients is about 1% to 2%, the incidence of thyroid papilloma (about 85% of all thyroid cancer) is 10% to 20%, the most common fusion partners include KIF5B, TRIM, CCDC6 and NCOA4The incidence of RET gene mutations in thyroid myelin cancer is about 60%, the most common mutation point is M918TFDA approval of LOXO-292 is based on the results of a clinical trial involving patients with three types of tumorsDuring clinical trials, patients took 160mg LOXO-292 orally twice daily until the disease progressed or became intolerant of toxicityThe primary end indicator of efficacy is the Overall Remission Rate (ORR), which reflects the percentage of patients with tumor reduction and the duration of the relief (DOR)evaluated the efficacy of LOXO-292 to NSCLC in 105 adult patients with RET fusion-positive NSCLC treated with platinum-based chemotherapyThe ORR in 105 patients was 64%Of the patients who responded to the treatment, 81% of the patients responded for at least six monthsThe efficacy of 39 PATIENTS WITH RET fusion-positive NSCLC who had never been treated was also evaluatedThe ORR in these patients was 84%Of the patients who responded to the treatment, 58% of the patients responded for at least six monthsevaluated the efficacy of LOXO-292 on MTC in PATIENTs aged 12 and older with RET mutant MTC (thyroid myeloma)The study recruited 143 patients who had previously received late-stage or metastatic RET mutationMTC for cabozantinib, vandetanib, or both drugs, as well as patients with advanced or metastatic RET mutationMTC who had not been treated with caboztinib, vandetanib, or both drugs The ORR in 55 patients who had previously been treated was 69% Seventy-six percent of patients who responded to treatment lasted at least six months The trial also evaluated the efficacy of 88 patients who had not previously been treated with MTC-approved therapy The ORR in these patients was 73% Sixty-one percent of patients who responded to treatment lasted at least six months evaluated the efficacy of LOXO-292 against RET-positive thyroid cancer in adults and pediatric patients over 12 years of age The study recruited 19 patients with 19 cases of radioactive iodine (RAI) refractory RET fusion-positive thyroid cancer and received another previous systemic treatment, and 8 patients with RAI refractory RET fusion-positive thyroid cancer who did not receive any other treatment The ORR in the 19 patients who had previously been treated was 79% Eighty-seven percent of patients who responded to the treatment lasted at least six months The trial also evaluated the efficacy of eight patients who had not received any treatment other than RAI The ORR in these patients was 100% Seventy-five percent of patients who responded to treatment lasted at least six months May 9, the FDA approved Novartis Tabrecta (capmatinib, INC280) for the treatment of patients with late localized or metastatic MET14 jump mutations in NSCLC patients Tabrecta is an oral highly selective small molecule MET inhibitor that inhibits MET phosphorylation caused by the binding or MET amplification of liver cell growth factors, as well as the phosphate of MET-mediated downstream signaling proteins and the proliferation and survival of MET-dependent cancer cells Tabrecta was approved based on phase II study data called GEOMETRYmono-1 GEOMETRYmono-1 is a multicenter, open-label Phase II clinical study designed to assess the efficacy and safety of adult patients with advanced NSCLC with tabrecta single-drug therapy for EGFR wild type, ALK re-emission sour, and carrying MET amplification or mutation The study included 97 met met exons 14 jumping NSCLC patients, twice a day, at 400 mg The primary endpoint of the study was ORR, and the secondary endpoint was the mitigation duration (DOR) results showed that Tabrecta had 68% ORR for first-time patients, 47% of patients with DOR over 12 months, 41% for patients who had received treatment in the past, and 32% for patients with remission durations of more than 12 months brain metastasis, the efficacy was also very good, 13 cases of met14 mutation of brain metastasis, intracranial ORR reached 54%, of which 4 cases of all brain metastasis were completely alleviated to reach CR superior ORR data in the primary treatment group compared to the treated patient group illustrated the clinical correlation between early diagnostic testing and early treatment May 8, AstraZeneca and Mersadon jointly announced that the heavy-duty PARP inhibitor lynparza, developed by both parties, had been approved by the FDA to extend the indications, with beba monoantigen as a first-line maintenance therapy for ovarian patients who had entered full or partial remission after platinum-based chemotherapy Tumors in these patients are positive for homologous recombinant defects (HRD-plus), defined as containing harmful BRCA gene mutations, and/or genomic instability this approval is based on the results of a randomized double-blind clinical trial called PAOLA-1 In this study, ovarian cancer patients were treated with Olapari and bevacizumab, or placebo and bevacizumab Bevacizumab is a VEGF-A inhibitor that is the standard treatment for this type of patient The first-time patients who were included in the FIGOIIIb-IV phase of high-level plasma or endometrial ovarian cancer, fallopian tube splicing or primary peritoneal cancer and other non-mucus epithelial ovarian cancer were fully or partially alleviated after combining beevardo monoline therapy with platinum sequoia chemotherapy, and could be admitted to the group regardless of surgical progonson or BRCA mutation patients were randomly assigned to take atotalis (300 mg, twice a day) or placebo at a 2:1 ratio for a total of 24 months, and all patients received bebabeli-resistant treatment every 3 weeks at a dose of 15 mg/kg for a total of 15 months results showed that of the 387 patients with HRD-positive tumors, the median progression survival of the Olapari combination therapy treatment group reached 37.2 months, compared with 17.7 months in the control group (HR-0.33, 95% CI:0.25-0.45) The patient's total lifetime (OS) data is not yet mature a new drug from research and development to the market is not so easy, many new drugs die at an early stage, there are some drugs adhere to the third phase of clinical, but lost in the final data But there are still some drugs with clinical data that have been tested and finally come to us It has to be said that this is a time full of miracles, we must be firm lying confident that the future of medicine is getting better and better
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.